Inveltys (loteprednol etabonate ophthalmic suspension; Kala) 1% has been made available for the treatment of postoperative inflammation and pain following ocular surgery.
Inveltys is the first ocular steroid approved for twice-daily dosing for this indication; other ocular steroids are approved for 4 times daily dosing. The product utilizes the Company’s proprietary AMPPLIFY Mucus-Penetrating Particle technology to improve penetration into target tissues of the eye. The technology has demonstrated a greater delivery of the drug into ocular tissues vs current loteprednol etabonate-containing drugs. Data from two Phase 3 studies showed a greater proportion of patients treated with Inveltys having complete resolution of ocular inflammation and pain compared with placebo.
Inveltys is a sterile preserved ophthalmic suspension containing 10mg/mL of loteprednol etabonate and is supplied as 2.8mL in a 5mL bottle. The product contains the preservative benzalkonium chloride 0.01%, which may be absorbed by soft contact lenses. Contact lenses should be removed prior to instillation of drops and may be reinserted after 15 minutes following administration.
For more information visit Inveltys.com.
This article originally appeared on MPR